This week Lonza took over the reigns of two new US business units
from Cambrex after completing the largest acquisition in its
company history and also announced a capability expansion at its
Czech Republic site.
Contract manufacturer Lonza has completed its acquisition of two
Cambrex subsidiaries, research bioproducts and microbial
biopharmaceutical, in a move that is fuelled by its strategic move
Swiss custom manufacturing firm Lonza has entered into a joint
venture with investment management company Bio*One Capital to built
a $250m (€210m) large-scale mammalian cell culture plant in
Singapore, underlying Lonza's confidence...
Swiss chemicals firm and contract manufacturer Lonza fulfilled its
promise of stronger financial results in the first half of 2005,
with profits coming in at the lower end of the forecast range, but
still on target, reports Phil Taylor.
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
Swiss life-science company Lonza announced on Tuesday that it is to
strengthen the production of oligonucleotides - an emerging new
class of therapeutics consisting of short nucleic acid chains
interfering in the processing of genetic...